CG Oncology公布CORE-008研究Cx队列二期试验积极初步结果,评估高危BCG暴露及无应答患者膀胱灌注联合疗法

美股速递
May 15

CG Oncology公布了其CORE-008临床研究中Cx队列二期试验的积极初步数据。该试验旨在评估一种膀胱灌注联合疗法,用于治疗高危、对卡介苗暴露后无应答的膀胱癌患者。

试验结果显示,该联合治疗方案在患者中取得了令人鼓舞的初步疗效。这些数据为针对这一难治性患者群体的创新疗法开发提供了新的希望。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10